Press Releases

Hero overlay Cancer research Analyst Coverage Annual Report Proxy Materials Corporate Governance Events Presentations Financial Information Investor Disclaimer Press Releases Stock Information
MENLO PARK, Calif., Feb. 25, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of
February 25, 2022
MENLO PARK, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2021. Updates since our last earnings release Achieved record fourth quarter revenues of $36.0 million reflecting growth of 33% compared
February 15, 2022
MENLO PARK, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- PacBio announced today that its executives will be speaking virtually at the following investor conferences: 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 3:00 pm Eastern Time (12:00 pm Pacific Time) Cowen 42nd
February 9, 2022
MENLO PARK, Calif., Jan. 14, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of
January 14, 2022

Investor Contact

Pacific Biosciences of California, Inc.
1305 O’Brien Drive, Menlo Park, CA 94025
ir@pacb.com